HB8901, titled the Securing Innovation and Research from Adversaries Act, would bar the use of federal research funds for collaborations involving individuals or entities participating in federally funded research awards if the collaboration is with a foreign entity on a U.S. government restricted entity list, or with an individual associated with such an entity. The bill defines research collaboration broadly to include joint projects, co-authorship, data sharing, material transfers, joint labs, personnel exchanges, and other arrangements determined by the relevant agency.
The bill also directs the Office of Science and Technology Policy, in consultation with federal research agencies, to issue government-wide guidance to standardize compliance, definitions, and enforcement. It creates a case-by-case waiver process allowing agency heads to approve otherwise prohibited collaborations if necessary for U.S. national security or if the collaboration is essential for a clearly defined scientific, public health, or national security purpose that cannot reasonably be achieved otherwise. Agencies granting waivers must notify Congress within 30 days and provide the identity of the party, the justification, and any mitigation measures.
The bill’s impact would be to add a new federal restriction on how grant, contract, cooperative agreement, and other federally funded research awards may be used, affecting universities, research institutions, laboratories, contractors, and individual researchers that receive federal support. It would not directly amend a single existing statute so much as impose a new cross-cutting condition on federally funded research relationships, while tying compliance to multiple existing federal restricted-party lists used in export control, sanctions, defense, telecommunications, forced labor, and related national security regimes.
General sentiment from the available context appears neutral to supportive of a national-security-focused research security measure, but there is no recorded committee debate or vote history in the provided materials. The bill was introduced and referred to the House Committee on Science, Space, and Technology, suggesting it is still at an early stage. Likely points of contention include the breadth of the prohibited collaboration definition, the inclusion of many different restricted lists, the potential burden on academic and scientific collaboration, and whether the waiver process is sufficiently flexible to preserve legitimate research, public health, and international scientific cooperation.
The bill would create a new federal prohibition on using federally funded research awards for collaborations with entities or individuals tied to a wide range of U.S. government restricted lists, affecting recipients of federal research funding such as universities, labs, contractors, and other research performers. It would also require OSTP-issued implementation guidance and establish a waiver-and-notification framework for exceptions, thereby adding compliance obligations and oversight requirements to federal research funding programs.
No committee transcript or vote record was provided, so there is no documented floor or committee sentiment to summarize. Based on the bill text and title, the measure is framed as a national security and research integrity bill, which suggests support from lawmakers concerned about foreign adversary access to U.S.-funded research, while likely drawing caution from research institutions worried about overbreadth and administrative burden.
The main points of contention are likely to be the scope of the ban and the breadth of the term "research collaboration," which covers not only direct joint research but also co-authorship, data sharing, personnel exchanges, and other activities. Another likely issue is the use of multiple restricted entity lists, including China-related, sanctions, export-control, forced-labor, and other lists, which may be seen as necessary by supporters but overly expansive by critics. The waiver authority may also be debated: supporters may want strong national security controls, while opponents may argue the bill could chill legitimate scientific, public health, and academic cooperation even with waivers available.